Drug treatment of depression in the 1990s: An overview of achievements and future possibilities

Drugs

Volumn 52, Issue 5, 1996, Pages 625-638

  Möller, Hans Jürgen ^a   Volz, Hans Peter ^b  

^a UNIVERSITY OF MUNICH   (Germany)

^b FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CIMOXATONE; CITALOPRAM; CLOMIPRAMINE; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; ISOCARBOXAZID; LEVOPROTILINE; LOFEPRAMINE; MAPROTILINE; MIANSERIN; MIRTAZAPINE; MOCLOBEMIDE; MONOAMINE OXIDASE A INHIBITOR; MONOAMINE OXIDASE INHIBITOR; NORADRENALIN; NORTRIPTYLINE; PARGYLINE; PAROXETINE; PHENELZINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRANYLCYPROMINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VENLAFAXINE;

CLINICAL TRIAL; CONSTIPATION; DEPRESSION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; EJACULATION; HEART PALPITATION; HUMAN; META ANALYSIS; NAUSEA; NONHUMAN; NORADRENERGIC SYSTEM; ORTHOSTATIC HYPOTENSION; PSYCHOPHARMACOLOGY; RAT; REVIEW; SEROTONINERGIC SYSTEM; SOMNOLENCE; SWEATING; TASTE DISORDER; TREMOR; VERTIGO; XEROSTOMIA;

EID: 0029804472     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199652050-00001     Document Type: Review

References (84)

1. Kasper S, Möller HJ. Antidepressive Psychopharmakatherapie: selektive Serotonin-Wiederaufnahmehemmer (SSRI) als neues Wirkprinzip. Deutsches Arzteblatt 1995; 92: A428-34
2. Baldwin D, Johnson FN. Tolerability and safety of citalopram. Rev Contemp Pharmacother 1995; 6: 315-25
3. Harvey AT, Preskorn SH. Interactions of serotonin reuptake inhibitors with tricyclic antidepressants. Arch Gen Psychiatry 1995; 52: 783-4
4. Bech P. A meta-analysis of the antidepressant properties of serotonin reuptake inhibitors. Int Rev Psychol 1990; 2: 207-11
5. Grimsley SR, Jann MW. Paroxetine, sertraline, and fluvoxamine: new selective serotonin reuptake inhibitors. Clin Pharm 1992; 11: 930-56
6. Kasper S, Fuger J, Möller HJ. Comparative efficacy of antidepressants. Drugs 1992; 43 Suppl. 2: 11-23
7. Davis JM, Wang Z, Janicak PG. A quantitative analysis of clinical drug trials for the treatment of affective disorders. Psychopharmacol Bull 1993; 29: 175-81
8. Danish University Antidepressant Group. Citalopram: clinical effective profile in comparison with clomipramine. A controlled multicenter study. Psychopharmacol 1986; 90: 131-8
9. Danish University Antidepressant Group. Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicentre study. J Affect Disord 1990; 18: 289-99
10. Anderson IM, Tomenson BM. The efficacy of selective serotonin re-uptake inhibitors in depression: a meta-analysis of studies against tricyclic antidepressants. J Psychopharmacol 1994; 8: 238-49
11. Stuppaeck CH, Geretsegger C, Whitworth AB, et al. A multicenter double-blind trial of paroxetine versus amitriptyline in depressed inpatients. J Clin Psychopharmacol 1994; 14: 241-6
12. Geretsegger C, Stuppaeck CH, Mair M, et al. Multicenter double blind study of paroxetine and amitriptyline in elderly depressed inpatients. Psychopharmacology 1995; 119: 277-81
13. Montgomery SA, Kasper S. Comparsion of compliance between serotonergic reuptake inhibitors and tricyclic antidepressants: a meta-analysis. Int Clin Psychopharmacol 1995; 9 Suppl. 4: 33-40
14. Anderson IM, Tomenson BM. Treatment discontinuation with selective serotonin reuptake inhibition compared with tricyclic antidepressants: a meta-analysis. BMJ 1995; 310: 1433-8
15. Tyrer P, Marsden CA, Casey P, et al. Clinical efficacy of paroxetine in resistant depression. J Psychopharmacol 1987; 1: 251-7
16. Gagiano CA, Müller PGM, Fourie J, et al. The therapeutic efficacy of paroxetine: (a) an open study in patients with major depression not responding to antidepressants; (b) a double-blind comparision with amitriptyline in depressed outpatients. Acta Psychiatr Scand 1989; 80 Suppl. 350: 130-1
17. Beasley CM, Syler ME, Cunningham GE, et al. Fluoxetine in tricyclic refractory major depressive disorder. J Affect Disord 1990; 20: 193-200
18. Montgomery SA, Dufour H, Brion S, et al. The prophylactic efficacy of fluoxetine in unipolar depression. Br J Psychiatry 1988; Suppl. 3: 69-76
19. Doogan DP, Caillard V. Sertraline in the prevention of depression. Br J Psychiatry 1992; 160: 217-22
20. Montgomery SA, Rasmussen JG. Citalopram 20mg, citalopram 40mg and placebo in the prevention of relapse of major depression. Int Clin Psychopharmacol 1992; 6 Suppl. 5: 71-3
21. Montgomery SA, Dunbar G. Paroxetine is better than placebo in relapse prevention and the prophylaxis of recurrent depression. Int Clin Psychopharmacol 1993; 8: 189-95
22. Raskin A, Schulterbrandt JG, Reatig N, et al. Depression subtypes and response to phenelzine, diazepam and placebo. Arch Gen Psychiatry 1974; 30: 66-75
23. Paykel ES, White JL. A European study of views on the use of monoamine oxidase inhibitors. Br J Psychiatry 1989; 155 Suppl. 6: 9-17
24. Johnston JP. Some observations upon a new monoamine oxidase inhibitor in brain tissue. Biochem Pharmacol 1968; 17: 1285-97
25. Laux G, Volz HP, Möller HJ. Newer and older monoamine oxidase inhibitors: a comparative profile. CNS Drugs 1995; 3: 145-58
26. Waldmeier PC. On the reversibility of reversible MAO inhibitors. Naunyn Schmiedebergs Arch Pharmacol 1985; 169: 305-10
27. Anderson C, Waldmeier PC, Tipton KF. The inhibition of monoamine oxidase by brofaromine. Biochem Pharmacol 1991; 41: 1871-7
28. Bieck PR, Antonin KH. Oral tyramine pressor test and the safety of monoamine oxidase inhibitor drugs: comparison of brofaromine and tranylcypromine in healthy subjects. J Clin Psychopharmacol 1988; 8: 237-45
29. Bieck PR, Antonin KH. Tyramine potentiation during treatment with MAO inhibitors: brofaromine and moclobemide vs. irreversible inhibitors. J Neural Transm 1989; 28 Suppl.: 21-31
30. Gleiter CH, Mühlbauer B, Schulz RM, et al. Monoamine oxidase inhibition by the MAO-A inhibitors brofaromine and clorgyline in healthy volunteers. J Neural Transm Gen Sect 1994; 95: 241-5
31. Volz HP, Gleiter CH, Struck M, et al. Brofaromine: insight into the nature of drug development. CNS Drugs 1995; 3: 1-8
32. Volz HP, Gleiter CH, Waldmeier PC, et al. Brofaromine - a review of its pharmacological properties and therapeutic use. J Neural Transm Park Dis Dement Sect 1996; 103: 217-45
33. Versiani M, Oggero U, Alterwain P, et al. Moclobemide in the treatment of major depressive episodes - a double-blind comparative multicenter trial vs. imipramine and placebo. Br J Psychiatry 1989; 155: 72-9
34. Bakish D, Bradwejn N, Nair N, et al. A comparison of moclobemide, amitriptyline and placebo in depression: a Canadian multicentre study. Psychopharmacol 1992; 106: 98-101
35. Larsen JK, Holm P, Hoyer E, et al. Moclobemide and clomipramine in reactive depression: a placebo-controlled randomized clinical trial. Acta Psychiatr Scand 1989; 79: 530-6
36. Casacchia M, Carolei A, Barba C, et al. A placebo-controlled study of the antidepressant activity of moclobemide, a new MAO-A inhibitor. Pharmacopsychiatry 1994 17: 122-5
37. Botte L, Evrard JC, Gilles C, et al. Controlled comparison of RO 11-1163 (moclobemide) and placebo in the treatment of depression. Acta Psychiatr Belg 1992; 92: 355-69
38. Laux G. Kontrollierte Vergleichsstudien mit Moclobemid in der Depressionsbehandlung. Psychopharmakotherapie 1994; 1: 9-18
39. Larsen JK, Gjerris A, Holm P, et al. Moclobemide in depression: a randomized trial against isocarboxazide and clomipramine emphazising atypical depression. Acta Psychiatr Scand 1991; 84: 564-70
40. Danish University Antidepressant Group. Moclobemide: a reversible MAO-A inhibitor showing weaker antidepressant effect than clomipramine in a controlled multicentre study. J Affect Disord 1993; 28: 105-16
41. Heinze C. Moclobemide versus tranylcypromine in the treatment of depression: a double-blind comparative study [abstract]. Psychopharmacol 1988; Suppl 96.: 11.41.10
42. Heinze G, Rossel L, Gabelic I, et al. Double-blind comparison of moclobemide and tranylcypromine in depression. Pharmacopsychiatry 1993; 26: 240-5
43. Gabelic I, Kuhn B. Moclobemide (Ro 11-1163) versus tranylcypromine in the treatment of endogenous depression [abstract]. Acta Psychiatr Scand 1990; 82 Suppl. 360: 63
44. Rossel L, Moll E. Moclobemide versus tranylcypromine in the treatment of depression. Acta Psychiatr Scand 1990; 82 Suppl. 360: 61-2
45. Angst J, Stabl M. Efficacy of moclobemide in different patient groups: a meta-analysis of studies. Psychopharmacol 1992; 106: S109-13
46. Moll E, Neumann N, Schmidt-Burgk W, et al. Safety and efficacy during long-term treatment with moclobemide. Clin Neuropharmacol 1994; 17 Suppl. 1: S74-87
47. Chen D, Ruck R. Safety of moclobemide in clincal use. Clin Neuropharmacol 1993; 16 Suppl. 2: S63-8
48. Wang CP, Howell SR, Scatina J, et al. The disposition of venlafaxine enantiomers in dogs, rats, and humans receiving venlafaxine. Chirality 1992; 4: 84-90
49. Muth ES, Haskins JT, Moyer HA, et al. Antidepressant biochemical profile of the novel bicyclic compound WY-45,030, an ethyl cyclohexanol derivative. Biochem Pharmacol 1986; 35: 4493-7
50. Muth EA, Moyer JA, Haskins JT, et al. Biochemical, neurophysiological, and behavioral effects of Wy-45,233 and other identified metabolites of the antidepressant venlafaxine. Drug Develop Res 1991; 23: 191-9
51. Feighner JP. The role of venlafaxine in rational antidepressant therapy. J Clin Psychiatry 1994; 55 Suppl. A: 62-8
52. 14C-venlafaxine in mouse, rat, dog, rhesus monkey and man. Xenobiotica 1993; 23: 349-59
53. Bolden-Watson C, Richelson E. Blockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomes. Life Sci 1993; 52: 1023-9
54. Bouchard JM, Peze E, Daurignac I. The Venlafaxine French Inpatient Study Group: a double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. Int Clin Psychopharmacol. In press
55. Preskorn SH. Antidepressant drug selection: criteria and options. J Clin Psychiatry 1994; 55: Suppl. A: 6-22
56. Sitsen JMA, Zivkov M. Mirtazapine: clinical profile. CNS Drugs 1995; 4 Suppl. 1: 39-48
57. Clement HH, Gemsa D, Weseman W. The effect of noradrenergic drugs on serotonin metabolism in the nucleus raphe dorsalis of the rat, studied by in vitro voltometry. Eur J Pharmacol 1992; 217: 43-8
58. 2 antagonist ORG 3770 enhances serotonin transmission in vivo. Eur J Pharmacology 1994; 253: R5-6
59. 2-selective adrenoceptor antagonist Org 3770 (mirtazapine, Remeron®) enhances noradrenergic and serotonergic transmission. Hum Psychopharmacol 1995; 10: S107-18
60. 1A-mediated serotonergic neurotransmission. CNS Drugs 1995; 4 Suppl. 1: 29-38
61. de Boer T, Maura G, Raiteri M, et al. Neurochemical and autonomic pharmacological profiles of the 6-aza-analogue of mianserin: Org 3770 and its enantiomers. Neuropharmacology 1988; 27: 399-408
62. Richou H, Ruimy P, Charbaut J, et al. A multicentre, double-blind, clomipramine-controlled efficacy and safety study of Org 3770. Hum Psychopharm 1995 Jul-Aug; 10: 263-71
63. Marttila M, Jaaskelainen J, Jarvi R, et al. A double-blind study comparing the efficacy and tolerability of mirtazapine and doxepin in patients with major depression. Eur Neuropsychopharmacol 1995 Dec; 5: 441-6
64. van Moffaert M, de Wilde J, Verreecken A, et al. Mirtazapine is more effective than trazodone: a controlled study in hospitalized patients with major depression. Int Clin Psychopharmacol 1995; 10: 3-9
65. Bremner JD. A double-blind comparison of Org 3770, amitriptyline, and placebo in major depression. J Clin Psychiatry 1995 Nov; 56: 519-25
66. Smith WT, Glaudin V, Panagides J, et al. Mirtazapine vs amitriptyline vs placebo in the treatment of major depressive disorder. Psychopharmacol Bull 1990; 26: 191-6
67. Montgomery SA. Safety of mirtazapine: a review. Int Clin Psychopharmacol 1995; 10 Suppl. 4: 37-45
68. Taylor DP, Carter RB, Eison AS, et al. Pharmacology and neurochemistry of nefazodone, a novel antidepressant. J Clin Psychiatry 1995; 54 Suppl. 6: 3-11
69. Dubobsky SL, Thomas M. Serotonergic mechanisms and current and future psychiatric practice. J Clin Psychiatry 1995; 56 Suppl. 2: 38-48
70. Eison AS, Eison MS, Torrente JR, et al. Nefazodone: preclinical pharmacology of a new antidepressant. Psychopharmacol Bull 1990; 26: 311-5
71. Sussman N. The potential benefits of serotonin receptor-specific agents. J Clin Psychiatry; 55 Suppl.: 45-51
72. Sharpley AL, Walsh AE, Cowan PJ. Nefazodone - a novel antidepressant - may increase REM sleep. Biol Psychiatry 1992; 31: 1070-3
73. Armitage R, Roffwarg H, Cain J, et al. The effect of nefazodone on sleep EEG in major depression. Neuropsychopharmacol 1994; 10: 123-7
74. Nefazodone: the latest FDA approved antidepressant [editorial]. Int Drug Ther Newslett 1995; 30: 17-20
75. Gammans R, Schwiderski U, O'Brien K, et al. Nefazodone efficacy in severe depression [abstract]. Clin Neuropharmacol 1992; 15 Suppl. 1 Pt B: 332B
76. Feighner JP, Pambakian R, Fowler RC, et al. A comparison of nefazodone, imipramine and placebo in patients with moderate to severe depression. Psychopharmacol Bull 1989; 25: 219-21
77. Dassylva B, Fontaine R, Gammans D, et al. Efficacy of nefazodone in patients suffering from major depressive disorder and panic disorder [abstract]. Biol Psychiatry 1992; 31: 169A
78. Rickels K, Schweitzer E, Clary C, et al. Nefazodone and imipramine in major depression: a placebo-controlled trial. Br J Psychiatry 1994; 164: 802-5
79. Fontaine R, Ontiveros A, Elle R, et al. A double-blind comparison of nefazodone, imipramine, and placebo in major depression. J Clin Psychiatry 1994; 55: 234-41
80. Anton SF, Robinson DS, Roberts DL, et al. Long-term treatment of depression with nefazodone. Psychopharmacol Bull 1994; 30: 165-9
81. Serzone®. Product information. Bristol-Myers Squibb, Princeton, New Jersey, USA, 1995
82. Peroutka SJ, Sleight AJ, McCarthy BG, et al. The clinical utility of pharmacological agents that act at serotonin receptors. J Neuropsychiatry 1989; 1: 253-62
83. Bressa GM. S-adenosyl-1-methionine (SAMe) as antidepressant: a meta-analysis of clinical studies. Acta Neurol Scand 1994; Suppl. 154: 7-14
84. Cimino M, Vantini G, Algeri S, et al. Age-related modification of dopaminergic and beta-adrenergic receptor system: restoration to normal activity by modifying membrane fluidity with S-adenosylmethionine. Life Sci 1984; 34: 2029-39